Tag: the war on (some) drugs

GOP Senators Tell DEA To Reject Marijuana Rescheduling, Arguing It Would Violate International Treaties

Three Republican senators are urging the Drug Enforcement Administration (DEA) to reject the top federal health agency’s marijuana rescheduling recommendation, arguing that it would put the U.S. out of compliance with international treaty obligations and make it harder to ensure that other countries continue to enforce drug laws, “including for deadly narcotics like fentanyl.”

In a letter sent to DEA Administrator Anne Milgram on Wednesday, Sens. Mitt Romney (R-UT), James Risch (R-ID) and Pete Ricketts (R-NE) said the agency should adhere to precedent and decline to move cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA), as the U.S. Department of Health and Human Services (HHS) has advised.

“Any effort to reschedule marijuana must be based on proven facts and scientific evidence—not the favored policy of a particular administration—and account for our treaty obligations,” the Senate Foreign Relations Committee members wrote.

“Marijuana is controlled under the Single Convention—which is not surprising given its known dangers and health risks—and the United Nation’s International Narcotics Control Board (INCB) has fiercely criticized efforts to legalize marijuana in other countries as a violation of the treaty,” they said.

The letter notes that the Senate ratified the Single Convention that contains drug policy mandates for member states in an unanimous vote in 1967. And they pointed out that DEA has previously cited international treaty obligations in denying past rescheduling petitions.

“It is important that the DEA continues to follow the law and abide by our treaty commitments,” they said, listing a series of questions they’re asking the agency to answer.

For example, the senators asked if DEA still considers it necessary to keep marijuana in either Schedule I or Schedule II to comply with the Single Convention, as it concluded under the Obama administration.

Keep reading

Germany’s Marijuana Legalization Bill Is Officially Signed Into Law And Will Take Effect On Monday

A bill to legalize marijuana nationwide in Germany has officially been signed into law, with the reform set to take effect next week.

Bundesrat President Manuela Schwesig signed the legislation on Wednesday, the last step to enactment. Usually German Federal President Frank-Walter Steinmeier would sign legislation, but because he’s currently away on vacation, that responsibility was handed down to the head of the legislative chamber representing individual states.

This comes one week after members of the Bundesrat reached a deal with Health Minister Karl Lauterbach and other government ministers and declined to refer the cannabis legislation to a mediation committee that would have delayed implementation by six months. Instead, the law will go into force on Monday as planned.

The Bundestag passed the marijuana legalization measure last month. The Bundesrat previously tried to block the proposed reform in September but ultimately failed.

Effective April 1, adults will be allowed to possess up to 25 grams of cannabis and grow up to three plants for personal use. Then, beginning July 1, adults could join “social clubs” where they could buy up to 25 grams of cannabis, with a cap of 50 grams per month. That cap is 30 grams for members under 21 years old.

Keep reading

Connecticut Lawmakers Approve Psilocybin Decriminalization Bill In Joint Committee Vote

Connecticut lawmakers have approved a bill to decriminalize psilocybin in a bicameral committee.

About two weeks after the legislature’s Joint Judiciary Committee first discussed the psychedelics proposal, members approved it on Tuesday.

The legislation would make possession of up to one-half an ounce of psilocybin punishable by a $150 fine, without the threat of jail time.

A second or subsequent violation would carry a fine of at least $200 but not more than $500. A person who pleads guilty or no contest on two separate occasions would be referred to a drug education program.

Police would be required to seize and destroy any amount of the psychedelic they find under the measure, HB 5297. Possession of more than a half-ounce of psilocybin would be considered a Class A misdemeanor.

Judiciary Committee Co-chair Rep. Steven Stafstrom (D) said the bill is partly about “recognizing that there has been quite a bit of study around this drug [and] recognizing the potential health benefits that veterans and others suffering from PTSD use it for and pushing in that direction.”

“Let’s be clear: This is not a legalization bill,” he said. “Possession of psilocybin under this bill would still be illegal. A police officer could still confiscate it could still destroy it and could issue an infraction ticket to someone in possession of small amounts of psilocybin.”

Keep reading

Delaware Treasurer Promotes New Marijuana Banking Bill To Provide State-Level Protections

Delaware’s treasurer is promoting new legislation that would provide state-level protections to banks that provide services to licensed marijuana businesses.

The bill was filed by Rep. Ed Osienski (D) and Sen. Trey Paradee (D) in partnership with state Treasurer Colleen Davis (D). It comes amid mounting pressure on Congress to enact federal cannabis banking reform.

The Delaware measure is designed to clarify that banks, credit unions, armored car services and accounting services providers are not subject to state-level prosecution simply for working with cannabis businesses.

“This Act aims to facilitate the operation of cannabis-related businesses by helping to ensure that such businesses have access to necessary financial and accounting services,” the bill synopsis says.

Davis, the treasurer, said in a press release last week that “H.B. 355 will provide state-level legal protection, and a clear legal framework for banks, payment processors, and other financial service providers to follow.”

“It can also ease concerns about federal enforcement and regulatory compliance among these businesses—since it allows them to demonstrate to federal agencies that they’re following a clear legal framework, ultimately leading to a safer and more transparent marijuana industry,” she said.

A press release from Davis’s office also says that, in addition to providing the basic protections, the bill would effectively boost the economy, enhance safety and promote competition.

“Across the country, we’ve witnessed dispensaries and banks alike struggling with legal uncertainty surrounding financial and accounting services for cannabis businesses,” Osienski, the House sponsor, said. “This uncertainty not only undermines the operations of state-compliant dispensaries but also hinders their access to basic business functions such as access to banking, acquiring loans, or paying taxes.”

Keep reading

House GOP Committee Urges Opposition To Marijuana Banking Bill, Saying ‘Gateway Drug’ Causes ‘Violence, Depression And Suicide’

A Republican House advisory committee is formally opposing marijuana banking legislation and a separate bill to remove past cannabis use as a disqualifying factor for federal employment and security clearances, while broadly criticizing the substance as a “gateway drug” that causes “violence, depression and suicide.”

The House Republican Policy Committee’s new marijuana report also says that Vice President Kamala Harris was “mistaken” when she said cannabis brings people “joy” as a 2020 presidential candidate, instead arguing that it is a “hazardous drug with short and long-term impacts.”

The guidance, which is meant to inform how the GOP caucus should approach marijuana policy issues, briefly describes the history of prohibition and the state legalization movement. It then makes the case that cannabis is a dangerous substance linked to mental health disorders such as schizophrenia, attributing that in part to “the high concentration of THC.”

The committee also cited questionable statistics to argue that state-level legalization is associated with increased violence. And it claimed that marijuana use causes workplace issues such as “decreased productivity, high unemployment claims, and lawsuits.”

“Instead of turning a blind eye to the dangers associated with marijuana and allowing states to have dispensaries on every corner, Congress should work to ensure that laws in relation to marijuana are enforced,” the guidance says.

It included two specific policy recommendations, stating that members should oppose the Secure and Fair Enforcement (SAFE) Banking and the Cannabis Users’ Restoration of Eligibility (CURE) Act.

That’s despite the fact that both measures enjoy bipartisan support, and certain members of the policy committee such as Reps. Tom McClintock (R-CA) and Nancy Mace (R-SC) have been vocal champions of marijuana reform. McClintock is signed onto the banking bill and Mace is the lead GOP cosponsor of the federal employment and security clearance measure.

Keep reading

Utah Governor Lets Psychedelics Pilot Program Bill Become Law Without His Signature, Citing ‘Overwhelming Support’

The Republican governor of Utah has allowed a bill to become law without his signature that authorizes a pilot program for hospitals to administer psilocybin and MDMA as an alternative treatment option.

Gov. Spencer Cox (R) said in a letter to legislative leaders last week that he was letting the psychedelics legislation become enacted despite his reservations due to the “overwhelming support” it received, with both chambers unanimously approving the measure.

“I am generally supportive of scientific efforts to discover the benefits of new substances that can relieve suffering,” Cox said. “However, we have a task force that was set up specifically to advise the Legislature on the best ways to study Psilocybin and I’m disappointed that their input was ignored.”

The governor didn’t specify which specific task force recommendations he wanted to see incorporated, but the panel did advise against authorizing the regulated use of psychedelics before they’re approved by the federal Food and Drug Administration (FDA).

Lawmakers have cited the panel’s findings to support advancing the pilot program legislation from Senate Majority Whip Kirk Cullimore (R) and House Speaker Pro Tempore James Dunnigan (R).

The newly enacted measure provides for that regulated access at two types of health care systems in the state. Psychedelics can be administered by a privately owned, non-profit health care system with at least 15 licensed hospitals or within medical programs operated by institutions of higher education.

“A healthcare system may develop a behavioral health treatment program that includes a treatment” with psilocybin and MDMA that it “determines is supported by a broad collection of scientific and medical research,” the bill says.

By July 1, 2026, any hospital that establishes a psychedelics therapy pilot program will need to submit a report to the legislature that details which drugs are being utilized, healthcare outcomes of patients and any reported side effects.

The legislation Cox allowed to become enacted will take effect on May 1, 2024 and sunset after three years.

Keep reading

California Bill Would Roll Back Marijuana Employment Protections For Law Enforcement Jobs

A California bill that was introduced last month as a minor technical fix to an existing law protecting workers from employment discrimination over legal marijuana use was substantially amended in committee this week with new section that would roll back the protections for various categories of workers, including those in law enforcement, coroners’ offices and animal control.

Under two pieces of legislation signed into law in 2022 and 2023, California employers are now prohibited from asking job applicants about past cannabis use, and most are barred from penalizing employees over lawful use of marijuana outside of the job.

The newly amended bill, SB 1264, sponsored by Sen. Shannon Grove (R), would remove those protections for “employees in sworn or nonsworn positions within law enforcement agencies who have or would have functions or activities” related to:

(1) The apprehension, incarceration, or correction of criminal offenders.
(2) Civil enforcement matters.
(3) Dispatch and other public safety communications.
(4) Evidence gathering and processing.
(5) Law enforcement records.
(6) Animal control.
(7) Community services duties.
(8) Public administrator or public guardian duties.
(9) Coroner functions.

The proposed change comes just months after the Commission on Peace Officer Standards and Training removed questions about marijuana from police job application forms. Several forms, the commission said at the time, were “modified to remove inquiries about a candidate’s prior cannabis use.”

Grove’s amendments were adopted on Tuesday, and the legislation currently sits before the Senate Rules Committee.

Both employment protections laws took effect on January 1 of this year. With certain exceptions, “it is unlawful for an employer to request information from an applicant for employment relating to the applicant’s prior use of cannabis,” one of them says.

Keep reading

New Study Finds One Dose of LSD Could Effectively Treat Anxiety in Many Patients

After years of criminalization and marginalization, scientists have begun looking at LSD’s medical benefits more closely, so much so that the Food and Drug Administration just issued a groundbreaking stamp of approval. 

Biopharmaceutical company Mind Medicine announced March 7 that the FDA has awarded “breakthrough therapy” status to its trial of patients using MM120 (lysergide D-tartrate) to treat anxiety. MindMed chief medical officer Daniel Karlin explained what the trial approval means going forward. “A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need with morbidity and mortality associated with it,” he told CNN. The move allows the FDA to “engage more closely in drug development” and speeds up the road to final approval as the agency is involved throughout the process. 

MM120 is the codename for MindMed’s lysergide D-tartrate compound, which resembles and delivers similar effects to lysergic acid diethylamide, known more commonly as LSD. In its ongoing trial, which kicked off in 2022, MindMed has so far found that a single dose of MM120 led to a 48-percent rate of remission from generalized anxiety disorder after 12 weeks following the drug’s administration. Scientists also noted significantly improved clinical signs of generalized anxiety disorder among 65 percent of patients within three months. 

“The clinical improvement for many patients was more than double what we see with today’s standard of care,” Karlin said. “This occurred at all levels of anxiety, from moderate all the way up to severe.”

Keep reading

Top Advocacy Center for Protecting Children from Harms of Vaccines Publishes CDC Propaganda Condemning Marijuana as Parents and Children Nationwide Use it for Treating Vaccine Injuries

I have been reporting on the dangers of vaccines to children for almost 2 decades now, and one of the real tragedies of children who are vaccine damaged, is that the medical system ignores, or even worse denies, that vaccine injuries exist.

The most common childhood vaccine injuries, by far, are the horrible symptoms that occur with autism. The medical system, in general, wants the public to believe that autism is genetic and not environmental, so that they can completely deny the vaccine – autism connection, and develop pharmaceutical drugs instead. The most common type of pharmaceutical drug used to treat children with autism are psychiatric drugs, which are incredibly toxic and dangerous, as we have reported over the years.

This has forced most parents over the years to seek treatment for their vaccine-damaged children outside of the medical system, seeking out help from alternative health providers who understand the corruption and dangers of the pharmaceutical system, and many of these alternative healers have developed alternative, non-pharmaceutical treatments.

When those treatments are successful, they become a threat to the economic prosperity of the medical system, and the Big Pharma machine will do everything they can to destroy the credibility of these wholistic practitioners and condemn the treatments they use.

The most effective way that private pharmaceutical companies use to silence their competitors in alternative and natural health, is to use the U.S. Government medical agencies such as the FDA and the CDC to declare such treatments “illegal” and seek to prosecute those who use them.

I learned this firsthand myself back in the 2000s, as I published research and testimonies about how healing Virgin Coconut Oil can be, only to have the FDA attack me and declare that I was selling “unapproved drugs” simply because we pointed people to the actual research and testimonials of how healthy coconut oil is, while at the same time selling it.

In the past decade or so, one of the most amazing natural therapies that has brought great relief to parents of vaccine injured children labeled as “autistic,” is “medical marijuana”, also referred to as “medical cannabis.”

Many thousands of parents in this country over the past decade plus can testify to how medical marijuana has dramatically healed their child with autism, and made their family whole again.

So I was horrified to read an article this week from The Vaccine Reaction, which is published by the National Vaccine Information Center (NVIC), the nation’s oldest and most effective organization in the United States for supplying information to parents about the dangers of childhood vaccines, condemning the use of marijuana, a product that is becoming more and more available as State laws change, and which is used by so many parents and families across this nation to treat their children who suffer from vaccine injuries.

Keep reading

Study Shows Colorado Marijuana Products Are Overstating THC Potency, With Researcher Citing Possible ‘Lab Fraud’

Cannabis flower sold in Colorado claims to contain much more tetrahydrocannabinol, or THC, than it actually does, according to my findings published in the peer-reviewed journal Plos One.

THC is the psychoactive compound that is derived when cannabis flower—commonly referred to as “bud”—is heated through smoking or cooking.

Why it matters

Accurate THC reporting is a linchpin for medical patients, recreational consumers and the overall integrity of the cannabis industry. Medical and recreational flower is generally the same—the difference is in testing requirements, price, taxes and purchase limits. Misleading potency information can disrupt medical dosages, misguide recreational users and erode trust in an industry striving for legitimacy.

Consumers often associate higher THC levels in cannabis flower with superior quality, potentially leading to overpayment for products that may not meet their expectations. This misconception can also create incentives for cultivators, testing labs and dispensaries to generate higher THC numbers—whether through cultivation techniques or through testing fraud.

Additionally, testing for toxins, pesticides and total yeast and mold can also fall victim to falsification. Recent reports reveal instances where labs in New York and other states have passed products that should have failed. This casts doubt on the credibility of the broader testing processes in place.

Keep reading